MedAvail Holdings Reports Costs Associated with Exit/Disposal in Form 8-K Filing.

Trending News 🌥️

MEDAVAIL ($NASDAQ:MDVL): MedAvail Holdings Inc. (NASDAQ: MDVL), a technology-enabled provider of prescription medication services, recently filed a Form 8-K with the Securities and Exchange Commission (SEC) reporting costs associated with its exit/disposal activities. MedAvail is dedicated to providing convenient access to medications and other health services in retail and community settings. It employs a unique combination of technology and services to facilitate the ordering, fulfillment, delivery and payment of medications, while driving customer engagement and satisfaction. The Form 8-K filing details the costs associated with the company’s exit/disposal activities, which include in-process research and development activities and other costs related to the termination of certain contracts.

The filing also outlines expenses related to restructuring activities, such as personnel and consulting services, as well as non-cash expenses related to the impairment of certain assets. This filing provides investors an understanding of the company’s financial position and its ability to remain competitive in the industry.

Market Price

MedAvail Holdings, a publicly traded company, reported costs associated with its exit and disposal activities in its form 8-K filing on Monday. The stock opened at $0.2 and closed at the same price, a decrease of 2.6% from the previous closing price of $0.2. The filing detailed the costs, including severance and consulting fees, associated with the exit/disposal activities.

The filing did not provide any further details on the exit/disposal activities or their impact on the company’s financial performance. It is yet to be seen how the costs associated with this activity will impact the company’s future performance. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Medavail Holdings. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Medavail Holdings. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Medavail Holdings. More…

Key Ratios Snapshot

Some of the financial key ratios for Medavail Holdings are shown below. More…

Analysis

GoodWhale has conducted an analysis of the fundamentals of MEDAVAIL HOLDINGS, and based on the Star Chart, has determined that MEDAVAIL HOLDINGS has an intermediate health score of 4/10 with regard to its cashflows and debt. This means that MEDAVAIL HOLDINGS may be able to pay off its debt and fund its future operations. We classify MEDAVAIL HOLDINGS as a ‘cheetah’ type of company, meaning that they have achieved high revenue or earnings growth but are considered less stable due to lower profitability. Investors who are looking for strong asset and growth opportunities may be interested in this type of company. MEDAVAIL HOLDINGS has strong asset and growth prospects, but weak dividend and profitability metrics. In other words, investors should know that while MEDAVAIL HOLDINGS may offer solid growth opportunities, there is also some risk involved. More…

Peers

The competition in the pharmaceutical retail industry is heating up. All these companies are vying for a share of the pie in this rapidly growing industry.

– China Jo-Jo Drugstores Inc ($NASDAQ:CJJD)

China Jo-Jo Drugstores Inc is a holding company that operates through its subsidiaries. The Company, through its subsidiaries, is engaged in the retail sale of pharmaceutical and other health and wellness products, as well as general merchandise in China. As of December 31, 2016, the Company operated a total of 522 retail pharmacies.

– Rite Aid Corp ($NYSE:RAD)

Rite Aid Corp is a pharmacy chain in the United States. As of 2022, it has a market capitalization of 334.12 million and a return on equity of 240.91%. The company operates through its pharmacy chain, which offers prescription drugs and other health and beauty products. It also operates a pharmacy benefit management business, which provides pharmacy services to third-party payers.

– Vaso Corporation ($OTCPK:VASO)

Vaso Corporation is a medical device company that develops, manufactures, and markets medical products for the treatment of vascular diseases and disorders. The company’s products include stents, catheters, and other devices used in the treatment of peripheral artery disease, coronary artery disease, and other vascular conditions. Vaso’s products are sold in over 50 countries worldwide. The company has a market cap of 33.33M as of 2022 and a Return on Equity of 28.83%.

Summary

MedAvail Holdings is a publicly traded health care technology company based in the United States. The company provides retail pharmacy, home delivery, and telemedicine services to retail pharmacies, hospitals, and clinics. Investing in MedAvail Holdings entails analyzing the company’s financial performance, growth prospects, and competitive environment. Its most recent 8-K filing reveals that the company has incurred costs associated with exiting and disposing certain technologies, which is a factor to consider when assessing the company’s future profitability. Investors should also consider MedAvail Holdings’ presence in the rapidly changing health care technology space and its ability to stay competitive with its product offerings.

Additionally, investors should review the company’s financials for any red flags such as deteriorating liquidity, significant debt levels, or weak margins. Understanding the fundamentals of the business is essential for any investor looking to invest in MedAvail Holdings.